Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multimodality treatment for inoperable poor-prognosis sinonasal tumors
2013-000580-93Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin, fluorouracil, etoposide, doxorubicin and 2 more in Nasal neoplasm, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival at 5 years. Started Mar 2013; status: completed.
02
Drugs
docetaxelcisplatinfluorouraciletoposidedoxorubicin
03
Conditions
Nasal neoplasm
Beyond the preview
Go deeper on 2013-000580-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000580-93.